ATE390633T1 - Reagens zum nachweis eines morbus-alzheimer- risikofaktors, nachweiskit dafür und verfahren zum nachweis eines morbus-alzheimer-risikofaktors unter verwendung davon - Google Patents

Reagens zum nachweis eines morbus-alzheimer- risikofaktors, nachweiskit dafür und verfahren zum nachweis eines morbus-alzheimer-risikofaktors unter verwendung davon

Info

Publication number
ATE390633T1
ATE390633T1 AT02800770T AT02800770T ATE390633T1 AT E390633 T1 ATE390633 T1 AT E390633T1 AT 02800770 T AT02800770 T AT 02800770T AT 02800770 T AT02800770 T AT 02800770T AT E390633 T1 ATE390633 T1 AT E390633T1
Authority
AT
Austria
Prior art keywords
alzheimer
detecting
risk factor
disease risk
apolipoprotein
Prior art date
Application number
AT02800770T
Other languages
English (en)
Inventor
Shigeo Ota
Masahiro Maeda
Original Assignee
Immuno Biological Lab Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Biological Lab Co Ltd filed Critical Immuno Biological Lab Co Ltd
Application granted granted Critical
Publication of ATE390633T1 publication Critical patent/ATE390633T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02800770T 2001-10-04 2002-10-04 Reagens zum nachweis eines morbus-alzheimer- risikofaktors, nachweiskit dafür und verfahren zum nachweis eines morbus-alzheimer-risikofaktors unter verwendung davon ATE390633T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001308465 2001-10-04

Publications (1)

Publication Number Publication Date
ATE390633T1 true ATE390633T1 (de) 2008-04-15

Family

ID=19127771

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02800770T ATE390633T1 (de) 2001-10-04 2002-10-04 Reagens zum nachweis eines morbus-alzheimer- risikofaktors, nachweiskit dafür und verfahren zum nachweis eines morbus-alzheimer-risikofaktors unter verwendung davon

Country Status (6)

Country Link
US (1) US20050266501A1 (de)
EP (1) EP1434053B1 (de)
JP (1) JP4153873B2 (de)
AT (1) ATE390633T1 (de)
DE (1) DE60225821T2 (de)
WO (1) WO2003031971A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GB2408508A (en) 2003-11-28 2005-06-01 Astrazeneca Ab Apolipoprotein antibodies
US7612179B2 (en) 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
WO2007092380A2 (en) * 2006-02-06 2007-08-16 Berkeley Heartlab, Inc. Apolipoprotein e genotyping and accompanying internet-based health management system
JP2009531712A (ja) * 2006-03-23 2009-09-03 デ グスマン ブレイヤー、エメリタ アポリポタンパク質フィンガープリント技術
DE102006056337A1 (de) * 2006-11-29 2008-06-05 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (de) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
GB0921447D0 (en) * 2009-12-04 2010-01-20 Randox Lab Ltd Assay
EP2558494B1 (de) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta-bindende proteine
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
EP2847218A4 (de) * 2012-05-08 2015-12-30 Univ Ramot Apoe4-antikörper zur behandlung neurodegenerativer erkrankungen
GB2511525A (en) * 2013-03-05 2014-09-10 Randox Teoranta Methods and Compositions for the Diagnosis of Alzheimer's Disease
KR101509641B1 (ko) * 2013-05-08 2015-04-06 경북대학교 산학협력단 아포지단백질 m을 포함하는 알츠하이머 질환 진단용 마커 조성물
EP3163303A1 (de) * 2015-11-02 2017-05-03 Biocross, S.L. Verfahren für apolipoproteinnachweis
EP3309550A1 (de) * 2016-10-12 2018-04-18 sphingotec GmbH Verfahren zum nachweis von apolipoprotein e4
CN117607456A (zh) * 2017-07-31 2024-02-27 奎斯特诊断投资有限公司 通过质谱法进行的载脂蛋白e同种型检测
CN112362876B (zh) * 2020-08-06 2023-12-15 武汉天德生物科技有限公司 一种检测早期老年痴呆症的胶体金试纸条及其制备方法
CN112540179B (zh) * 2020-08-06 2023-07-07 武汉天德生物科技有限公司 一种测试ApoE4蛋白含量的ELISA试剂盒
CN112540178B (zh) * 2020-08-06 2023-12-19 武汉天德生物科技有限公司 一种检测早期老年痴呆症的免疫组化试剂盒及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US19821A (en) * 1858-03-30 Improvement in cotton-presses
US5472858A (en) * 1991-06-04 1995-12-05 Wisconsin Alumni Research Foundation Production of recombinant proteins in insect larvae
WO1994009155A1 (en) * 1992-10-13 1994-04-28 Duke University Methods of detecting alzheimer's disease
US5773220A (en) * 1995-07-28 1998-06-30 University Of Pittsburgh Determination of Alzheimer's disease risk using apolipoprotein E and .alpha.
JP3397066B2 (ja) * 1996-12-27 2003-04-14 富士レビオ株式会社 免疫学的測定方法を用いたアポ蛋白ｅフェノタイプの同定方法
US20010019821A1 (en) * 1999-03-31 2001-09-06 Smith Jack V. Method for manufacturing and detecting and normalizing HIV for rapid analysis

Also Published As

Publication number Publication date
WO2003031971A1 (fr) 2003-04-17
EP1434053B1 (de) 2008-03-26
JP4153873B2 (ja) 2008-09-24
EP1434053A4 (de) 2005-11-30
US20050266501A1 (en) 2005-12-01
DE60225821D1 (de) 2008-05-08
JPWO2003031971A1 (ja) 2005-01-27
DE60225821T2 (de) 2009-04-30
EP1434053A1 (de) 2004-06-30

Similar Documents

Publication Publication Date Title
DE60225821D1 (de) Reagens zum nachweis eines morbus-alzheimer-risikofaktors, nachweiskit dafür und verfahren zum nachweis eines morbus-alzheimer-risikofaktors unter verwendung davon
TW200745556A (en) Biomarkers for liver fibrotic injury
ATE356884T1 (de) Methode zur detektion von pathogenen organismen
ATE230801T1 (de) Verfahren zur detektion von zielnukleinsäure, verfahren zu ihrer quantifizierung und pyrylium- verbindungen zur chemilumineszenz-analyse
PT1329724E (pt) Dispositivo e metodo de doeseamento de lipoproteina de alta densidade
DE60233060D1 (de) Schnellnachweis replizierender zellen
DE602004020327D1 (de) Verfahren zur Detektierung von Temperaturänderungen
ATE299533T1 (de) Methode und kit zum auffinden, zum nachweis und/oder zur quantifizierung von transkriptionsfaktoren
DE625212T1 (de) Verfahren zum entdecken von krankheit von alzheimer.
WO2004000884A3 (fr) Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100
ATE151883T1 (de) Verfahren zum nachweis freier igf-i, igf-ii, und gh spiegel in körperflüssigkeiten
WO2005016515A3 (en) Colorable microspheres for dna and protein microarray
DE602005019600D1 (de) Systeme und verfahren zur auswertung der wirksamkeit von enzymen
ATE321881T1 (de) Sonde zur erkennung und identifizierung von helicobacter pylori
ATE309544T1 (de) Verfahren und vorrichtung zur quantifizierung von lipoprotein-cholesterol hoher dichte
DE69833660D1 (de) Nukleinsäuresonden zur detektion von candida-spezies
WO2005080594A3 (en) Method for determining the risk of developing a neurological disease
ATE555385T1 (de) N1,n12-diacetylspermin als tumormarker
EP1132483A3 (de) Methode zur Diagnose von Schizophrenie unter Verwendung objektiver Indizes
FR2805545B1 (fr) Procede electrochimique de detection d'acides nucleiques
DE60142066D1 (de) Verfahren zum nachweis von norwalk-ähnlichem virus (gi)
ATE409742T1 (de) Von bacillus cereus produzierte cereulid-synthase,diese codierendes gen und verfahren zum nachweis von cereulid
ATE353978T1 (de) Personalisierte mikroarrays and ihre verwendung zum nachweis von zielmolekülen
Laude A direct plaque assay for hog cholera virus
DE602004020603D1 (de) Verfahren zum nachweis des gens einer mutante des pankreatischen insel-amyloidproteins sowie nukleinsäuresonde und kit dafür

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties